
---
title: '恒瑞医药：SHR-1816注射液临床试验获批'
categories: 
 - 金融
 - 证券时报网
 - 快讯
headimg: 'https://picsum.photos/400/300?random=7507'
author: 证券时报网
comments: false
date: Wed, 09 Mar 2022 16:54:00 GMT
thumbnail: 'https://picsum.photos/400/300?random=7507'
---

<div>   
<p>证券时报e公司讯，<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SS600276" style="color: #2f67d1;text-decoration: none;" code="600276" target="_blank">恒瑞医药</a>(600276)3月9日晚间公告，子公司北京盛迪医药、上海<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SS600276" style="color: #2f67d1;text-decoration: none;" code="600276" target="_blank">恒瑞医药</a>收到国家药监局核准签发关于SHR-1816注射液的《药物临床试验批准通知书》。SHR-1816注射液临床拟皮下注射用于治疗成人糖尿病。</p>

                  
</div>
            